Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines
Authors Jongen P, Lemmens W, Hupperts R, Hoogervorst E, Schrijver H, Slettenaar A, de Schryver E, Boringa J, van Noort E, Donders R
Received 10 March 2016
Accepted for publication 18 April 2016
Published 24 May 2016 Volume 2016:10 Pages 909—917
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Johnny Chen
Peter Joseph Jongen,1,2 Wim A Lemmens,3 Raymond Hupperts,4 Erwin LJ Hoogervorst,5 Hans M Schrijver,6 Astrid Slettenaar,7 Els L de Schryver,8 Jan Boringa,9 Esther van Noort,10 Rogier Donders3
1Department of Community and Occupational Medicine, University Medical Centre Groningen, University Groningen, Groningen, 2MS4 Research Institute, 3Department for Health Evidence, Radboud university medical center, Nijmegen, 4Department of Neurology, Zuijderland Medisch Centrum Sittard, Sittard, 5Department of Neurology, St Antonius Hospital, Nieuwegein, 6Department of Neurology, Multiple Sclerosis Centre, Westfries Gasthuis, Hoorn, 7Department of Neurology, Medisch Spectrum Twente, Enschede, 8Department of Neurology, Alrijne Ziekenhuis, Leiderdorp, 9Department of Neurology, Meander Medisch Centrum, Amersfoort, 10Curavista BV, Geertruidenberg, the Netherlands
Background: In multiple sclerosis patients, the persistence of, and adherence to, disease-modifying treatment are often insufficient. The degree of persistence and adherence may relate to the care received from various disciplines.
Methods: In an observational study of 203 patients treated with glatiramer acetate 20 mg subcutaneous daily, we assess the persistence and adherence in relation to the amount of care received in various disciplines. The frequencies and durations of care per discipline were reported by patients online, as were missed doses and eventual treatment discontinuation. The associations between the care provided by neurologists, nurses, psychologists, pharmacists, and rehabilitative doctors and persistence and adherence were the primary outcomes; the associations between care received from general practitioners, occupational therapists, physiotherapists, social workers, dieticians, home caregivers, informal caregivers, other medical specialists, and other caregivers and persistence and adherence were secondary outcomes.
Results: It was found that the 12-month persistence rate was 62% and that 85% of the persistent patients were 95% adherent (missed <5% of doses). Patients who discontinued treatment in the fourth quarter (Q) had received less-frequent and shorter psychological care in Q3 than persistent patients (P=0.0018 and P=0.0022). Adherent patients had received more frequent home care and informal care than nonadherent patients (P=0.0074 and P=0.0198), as well as longer home care and informal care (P=0.0074 and P=0.0318). Associations between care in other disciplines and persistence or adherence were not observed. As to the relationship between adherence and persistence, nonadherence in Q2 was related to discontinuation after Q2 (P=0.0001).
Conclusion: We obtained no evidence that, in multiple sclerosis patients, persistence of and adherence to disease-modifying treatment are associated with the amount of neurological, nursing, pharmaceutical, or rehabilitative care. However, findings suggest that the treatment of psychological problems in Q3 may relate to persistence and that home care and informal care may relate to adherence.
Keywords: home care, informal care, nursing, pharmaceutical, rehabilitative, psychological
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]